Physician profile
Michael David Ciliberti
NPI 1295734564
$18,241.75
in general payments reported to CMS, 2019-2025
40 companies · $4,477 in 2025
The $4,477 reported for 2025 was more than what 75% of Clinical & Laboratory Immunology (Allergy & Immunology) providers received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,408 · 2021: $2,661 · 2022: $2,500 · 2023: $2,950 · 2024: $2,933 · 2025: $4,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,256.65 |
| Education | $102.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,365.93 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $2,502.57 | 2019-2025 | |
| Csl Behring | $1,942.41 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,685.21 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $1,246.25 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $1,224.40 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,187.77 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Pfizer INC. | $547.15 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $432.85 | 2019-2025 | |
| Optinose US, INC. | $429.19 | 2019-2025 | |
| Genentech USA, INC. | $422.98 | 2019-2025 | Xolair |
| Amgen INC. | $370.73 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $343.52 | 2023-2025 | Ayvakit |
| Grifols USA, LLC | $333.30 | 2020-2025 | Xembify |
| Alk-Abello, INC | $298.57 | 2020-2025 | Grastek, Ragwitek, Odactra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $258.81 | 2019-2022 | |
| Kaleo, INC. | $243.25 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $214.06 | 2022-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $203.07 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.80 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Ionis Pharmaceuticals, INC. | $86.30 | 2025 | Dawnzera |
| Greer Laboratories, INC. | $86.24 | 2024-2025 | Oralair |
| Teva Pharmaceuticals USA, INC. | $70.53 | 2019-2021 | |
| Shire North American Group INC | $65.46 | 2019 | |
| Bio Products Laboratory USA, INC. | $57.71 | 2021-2023 | Gammaplex, Coagadex |
| Mylan Specialty L.P. | $57.12 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $55.41 | 2019-2023 | |
| Leo Pharma INC. | $49.50 | 2022 | |
| Aytu Biopharma, INC. | $47.54 | 2022-2023 | Karbinal |
| Biofire Diagnostics, LLC | $40.83 | 2020 | |
| Circassia INC. | $36.54 | 2019 | |
| Octapharma USA, INC. | $36.22 | 2019-2024 | Panzyga |
| Phadia US INC. | $33.00 | 2020-2023 | Immunocap |
| Sanofi-Aventis U.S. LLC | $28.68 | 2021 | |
| Uswm, LLC | $27.11 | 2021 | |
| Abbvie INC. | $24.99 | 2024 | |
| Hikma Pharmaceuticals USA | $18.72 | 2023 | Ryaltris |
| Lilly USA, LLC | $14.92 | 2025 | Ebglyss |
| Sunovion Pharmaceuticals INC. | $14.38 | 2019 | |
| Incyte Corporation | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ciliberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.